Condition: Sickle Cell Disease · Sponsor: University of Pittsburgh
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
This description comes directly from the study's public registry record.
Mikhil N Bamne, PhD · (412) 648-6920 · bamnemn2@upmc.edu
Jude Jonassaint, RN · 412-692-2086 · jonassaintjc@upmc.edu
Always discuss trial participation with your own doctor first.
| Magee Women's Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
| UPMC Montefiore | Pittsburgh, Pennsylvania, United States | Recruiting |
| UPMC Presbyterian | Pittsburgh, Pennsylvania, United States | Recruiting |
| Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04109820